NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 ( ALDH1A1 ) inhibitors with an IC 50 of 7 nM. In Vitro NCT-506 inhibits ALDH1A1, hALDH1A3, hALDH2 with IC 50 s of 0.007±0.001, 16.4±3.99, and 21.5 μM, respectively. NCT-506 (100, 10, 1, 0.1 μM, 6 days) decreases significantly cell viability with an EC 50 of 45.6 μM in OV-90 cells. NCT-506 inhibits MIA PaCa-2, OV-90, and HT-29 cells with IC 50 s of 0.077±0.040, 0.161±0.038, and 0.048±0.022 μM in aldefluor cell-based assays, respectively. NCT-506 is treated in combined with Paclitaxel, IC 50 s of 1202, 924, 870, 411, 102, and 31.8 nM with concentrations of NCT-506 at 0 (DMSO), 1, 3, 10, 20, 30 μM in SKOV-3-TR cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OV-90 and SKOV-3-TR cells Concentration: 100, 10, 1, 0.1 μM Incubation Time: 6 days for OV-90 cells; 4 days for SKOV-3-TR cells Result: Decreased significantly cell viability with an EC 50 of 45.6 μM in OV-90 cells. Decreased cell viability in combined treatments (Paclitaxel concentration of 100 nM) with an EC 50 of 11.2 μM in SKOV-3-TR cells. Form:Solid